Research

Balanced and strong product portfolio in gastrointestinal indications

At Movetis, our broad GI product portfolio consists of one approved product (Resolor), three products in clinical development, and two prioritised compounds out of its preclinical portfolio. We have also two extensive compound libraries. Together this portfolio addresses important areas of unmet GI medical need, including severe chronic constipation, ascites, paediatric reflux, and refractory reflux disease.

Our lead product, Resolor (prucalopride), has recently (in October 2009) received the marketing approval for the symptomatic treatment of chronic constipation (CC) in women in whom laxatives fail to provide adequate relief in the EU27 and Iceland, Liechtenstein and Norway. Prucalopride is also being tested for use in a number of other indications including chronic constipation in males and children as well as opioid-induced constipation and post operative ileus. Resolor is also under review by the Swiss authorities, Swissmedic. Resolor is the first in a new class of selective high affinity serotonin (dihydrobenzofurancarboxamide derivatives) with enterokinetic activity.

In addition to Resolor (prucalopride), we have advanced our other clinical and pre-clinical development programmes that now include two drug candidates in Phase II. M0002 is in Phase II development for ascites, while M0003 is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patients refractory to PPIs, and paediatric reflux. A third drug candidate, M0004, which is a backup to M0003, is in Phase I.

We have also two prioritised compounds out of our preclinical portfolio, M0014 and M0012 and two extensive compound libraries, which reinforce this portfolio.

At Movetis, we believe that this broad portfolio of compounds and drug candidates will enable us to focus on a diverse range of indications and underserved GI areas. It also positions us well for long-term growth and to achieve our goal of becoming a successful European GI specialty company.